Biostime provides pediatric nutrition and baby care products. The Company offers premium pediatric nutritional and baby care products to pregnant and nursing mothers and for their infants and children. Biostime's family of products includes premium and probiotic supplements for children, infant formulas and dried baby food.

According to Surperformance ratings, the group has strong fundamentals, both in terms of business predictability and valuation. In addition, analysts have recently revised upward their earnings estimates and now expect a profit of EUR 0.14 per share for the current year.

Biostime is in an uptrend in the medium and long term, but the last bearish movement returns close to a major support level. This threshold, if preserved, will enable to enjoy the bullish movement. The decline observed in the short term offers an interesting entry point for a mid-term investment.

Investors will take advantage of the current area to buy Biostime. The goalswill be set at HKD 19.38 and by extension HKD 23. The stop loss will be triggered below the HKD 17.1 support.